Anália Do Carmo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anália Do Carmo has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Ana Bela Sarmento-Ribeiro
Laboratório de Oncobiologia e Hematologia, Clinica Universitária de Hematologia, FMUC—Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
7 shared publications - Diana Matias
Gulbenkian Institute for Molecular Medicine (GIMM), Edifício Egas Moniz, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
7 shared publications - Maria Celeste Lopes
Universidade de Coimbra
7 shared publications - Maria Teresa Cruz
Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal
7 shared publications - Vivaldo Moura-Neto
Postgraduate Program in Medicine (Anatomical Pathology), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, Brazil
7 shared publications - Joana Balça-Silva
Center for Neuroscience and Cell Biology and Institute for Biomedical Imaging and Life Sciences (CNC.IBILI), Coimbra, Portugal; Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Instituto Estadual do Cérebro Paulo Niemeyer (IECPN) - Secretaria de Estado de Saúde, Rio de Janeiro, Brazil
6 shared publications
Latest Publications
- 16 November 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children
Background: Influenza is a major cause of respiratory illness, contributing substantially to morbidity and mortality in children. Seasonal influenza epidemics were profoundly disrupted by the coronavirus disease 2019 (COVID-19) pandemic. Whether the clinical presentation and disease severity differ according to influenza virus type and subtype remains incompletely understood. This study aimed to describe temporal changes in epidemiology, clinical characteristics, outcomes and healthcare utilization among laboratory-confirmed pediatric influenza cases over 11 seasons and to explore associations between virus type/subtype and clinically important outcomes. Methods: We conducted a retrospective observational study at a tertiary pediatric hospital, including all laboratory-confirmed influenza cases identified in children presenting with acute respiratory infection between July 2015 and June 2026, and analyzed the distribution of cases and their demographic and clinical characteristics. Results: Influenza was detected in 3105 children (median age, 4 years), the majority of whom were previously healthy (82.4%). Within this cohort, hospitalization was required in 17.9% of cases, with 1.1% requiring intensive care admission, and 22.8% developing complications, including encephalitis and sepsis. Influenza circulation patterns, including the timing of peak activity and the duration of annual epidemics, varied over time. After an 18-month absence of reported cases during the COVID-19 pandemic, the 2021–2022 season was marked by a substantial resurgence, followed by 2 years of atypical year-round circulation before returning to the usual seasonal pattern. Influenza A accounted for 72.3% of cases, with alternating predominance of virus types and subtypes without a consistent epidemiologic pattern. In a restricted type/subtype analysis, influenza A(H1N1) cases had a higher frequency of hospitalization and recorded moderate-to-severe complications, and this association remained statistically significant after multivariable analysis. Conclusions: Influenza was associated with clinically important illness and healthcare use among children in this hospital-based cohort, most commonly among otherwise healthy children, highlighting the importance of influenza prevention strategies. During and after the COVID-19 pandemic, influenza epidemiology changed markedly, underscoring the need for continued surveillance.
- 16 November 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children
Background: Influenza is a major cause of respiratory illness, contributing substantially to morbidity and mortality in children. Seasonal influenza epidemics were profoundly disrupted by the coronavirus disease 2019 (COVID-19) pandemic. Whether the clinical presentation and disease severity differ according to influenza virus type and subtype remains incompletely understood. This study aimed to describe temporal changes in epidemiology, clinical characteristics, outcomes and healthcare utilization among laboratory-confirmed pediatric influenza cases over 11 seasons and to explore associations between virus type/subtype and clinically important outcomes. Methods: We conducted a retrospective observational study at a tertiary pediatric hospital, including all laboratory-confirmed influenza cases identified in children presenting with acute respiratory infection between July 2015 and June 2026, and analyzed the distribution of cases and their demographic and clinical characteristics. Results: Influenza was detected in 3105 children (median age, 4 years), the majority of whom were previously healthy (82.4%). Within this cohort, hospitalization was required in 17.9% of cases, with 1.1% requiring intensive care admission, and 22.8% developing complications, including encephalitis and sepsis. Influenza circulation patterns, including the timing of peak activity and the duration of annual epidemics, varied over time. After an 18-month absence of reported cases during the COVID-19 pandemic, the 2021–2022 season was marked by a substantial resurgence, followed by 2 years of atypical year-round circulation before returning to the usual seasonal pattern. Influenza A accounted for 72.3% of cases, with alternating predominance of virus types and subtypes without a consistent epidemiologic pattern. In a restricted type/subtype analysis, influenza A(H1N1) cases had a higher frequency of hospitalization and recorded moderate-to-severe complications, and this association remained statistically significant after multivariable analysis. Conclusions: Influenza was associated with clinically important illness and healthcare use among children in this hospital-based cohort, most commonly among otherwise healthy children, highlighting the importance of influenza prevention strategies. During and after the COVID-19 pandemic, influenza epidemiology changed markedly, underscoring the need for continued surveillance.
- Open Access
- 12 December 2025
- Published by MDPI AG in Future Pharmacology
- Vol. 5 (4) , 73
In Vitro Antifungal Effect of Selected Essential Oils Against Clinical Isolates Causing Fungal Keratitis: A Preliminary Pharmacological Evaluation
Background/Objectives: Fungal keratitis (FK) is a current challenge in ophthalmology due to its association with severe visual impairment and the limitations of current antifungal therapies. We aim to evaluate the antifungal activity of essential oils (EOs) from the aromatic and medicinal plants Cymbopogon citratus and Lavandula pedunculata against selected FK pathogens collected from FK patients in two Portuguese hospitals. Methods: The antifungal activity of the EOs was tested at concentrations of 25%, 50%, 75%, and 100% for up to 7 days using the solid-phase disk diffusion in vitro assay. Results: Candida albicans was the most prevalent pathogen (28.6%), followed by Candida parapsilosis (21.4%) and Dicyma olivacea (14.2%). The other identified species were Aspergillus fumigatus and Scedosporium boydii (7.1%). Clinical diagnostic methodologies showed agreement with the molecular identification. Cymbopogon citratus EO showed higher antifungal activity than Lavandula pedunculata EO. The highest antifungal activity was observed against Aspergillus fumigatus and Scedosporium boydii (inhibition zone diameter, IZD = 90.0 mm) after 7 (Cymbopogon citratus EO) or 3 days of incubation (Lavandula pedunculata EO). While the antifungal activity of Cymbopogon citratus EO was maintained during the study (for Aspergillus fumigatus, Candida albicans, and Scedosporium boydii), the antifungal activity of Lavandula pedunculata EO decreased with time. Conclusions: Cymbopogon citratus EO and Lavandula pedunculata EO showed optimal antifungal activity against molds (Aspergillus fumigatus and Scedosporium boydii) after 3 days of incubation. Against yeasts (Candida albicans and Candida parapsilosis), the EOs showed lower activity. Our study sheds light on the development of new pharmacological strategies for FK based on EOs extracted from aromatic and medicinal plants.
- 12 December 2025
- Published by MDPI AG in Future Pharmacology
- Vol. 5 (4) , 73
Open AccessIn Vitro Antifungal Effect of Selected Essential Oils Against Clinical Isolates Causing Fungal Keratitis: A Preliminary Pharmacological Evaluation
Background/Objectives: Fungal keratitis (FK) is a current challenge in ophthalmology due to its association with severe visual impairment and the limitations of current antifungal therapies. We aim to evaluate the antifungal activity of essential oils (EOs) from the aromatic and medicinal plants Cymbopogon citratus and Lavandula pedunculata against selected FK pathogens collected from FK patients in two Portuguese hospitals. Methods: The antifungal activity of the EOs was tested at concentrations of 25%, 50%, 75%, and 100% for up to 7 days using the solid-phase disk diffusion in vitro assay. Results: Candida albicans was the most prevalent pathogen (28.6%), followed by Candida parapsilosis (21.4%) and Dicyma olivacea (14.2%). The other identified species were Aspergillus fumigatus and Scedosporium boydii (7.1%). Clinical diagnostic methodologies showed agreement with the molecular identification. Cymbopogon citratus EO showed higher antifungal activity than Lavandula pedunculata EO. The highest antifungal activity was observed against Aspergillus fumigatus and Scedosporium boydii (inhibition zone diameter, IZD = 90.0 mm) after 7 (Cymbopogon citratus EO) or 3 days of incubation (Lavandula pedunculata EO). While the antifungal activity of Cymbopogon citratus EO was maintained during the study (for Aspergillus fumigatus, Candida albicans, and Scedosporium boydii), the antifungal activity of Lavandula pedunculata EO decreased with time. Conclusions: Cymbopogon citratus EO and Lavandula pedunculata EO showed optimal antifungal activity against molds (Aspergillus fumigatus and Scedosporium boydii) after 3 days of incubation. Against yeasts (Candida albicans and Candida parapsilosis), the EOs showed lower activity. Our study sheds light on the development of new pharmacological strategies for FK based on EOs extracted from aromatic and medicinal plants.
- Open Access
- 3 October 2025
- Published by MDPI AG in Preprints.org
In Vitro Antifungal Effect of Selected Essential Oils Against Clinical Isolates Causing Fungal Keratitis: A Preliminary Pharmacological Evaluation
Background/Objectives: Fungal keratitis (FK) is a current challenge in ophthalmology, due to its association with severe visual impairment and limitations of current antifungal therapies. We aim to evaluate the antifungal activity of essential oils (EOs) from aromatic and medicinal plants Cymbopogon citratus and Lavandula pedunculata against selected FK pathogens collected from FK patients in two Portuguese hospitals. Methods: The antifungal activity of EOs was tested at concentration of 25%, 50%, 75%, and 100%, up to 7 days, through solid-phase disk diffusion testing in vitro assay. Results: Candida albicans were the more prevalent (28.6%), followed by Candida parapsilosis (21.4%) and Dicyma olivacea (14.2%). Other species identified were Aspergillus fumigatus and Scedosporium boydii (7.1%). Clinical diagnostic methodologies showed agreement with the molecular identification (data not shown). Cymbopogon citratus EO showed higher antifungal activity than Lavandula pedunculata EO. Highest antifungal activity was observed against Aspergillus fumigatus and Scedosporium boydii (inhibition zone diameter, IZD=90.0mm), up to 7 (Cymbopogon citratus EO) or 3 days of incubation (Lavandula pedunculata EO). While the antifungal activity of Cymbopogon citratus EO was maintained during the study (for Aspergillus fumigatus, Candida albicans and Scedosporium boydii), it decreases with time with Lavandula pedunculata EO. Conclusions: Cymbopogon citratus EO and Lavandula pedunculata EO showed optimal antifungal activity against molds (Aspergillus fumigatus and Scedosporium boydii), up to 3 days of incubation. Against yeasts (Candida albicans and Candida parapsilosis), the EOs showed lower activity. Our study shed light on developing new pharmacological strategies for FK based on EOs extracted from aromatic and medicinal plants.
- 3 October 2025
- Published by MDPI AG in Preprints.org
Open AccessIn Vitro Antifungal Effect of Selected Essential Oils Against Clinical Isolates Causing Fungal Keratitis: A Preliminary Pharmacological Evaluation
Background/Objectives: Fungal keratitis (FK) is a current challenge in ophthalmology, due to its association with severe visual impairment and limitations of current antifungal therapies. We aim to evaluate the antifungal activity of essential oils (EOs) from aromatic and medicinal plants Cymbopogon citratus and Lavandula pedunculata against selected FK pathogens collected from FK patients in two Portuguese hospitals. Methods: The antifungal activity of EOs was tested at concentration of 25%, 50%, 75%, and 100%, up to 7 days, through solid-phase disk diffusion testing in vitro assay. Results: Candida albicans were the more prevalent (28.6%), followed by Candida parapsilosis (21.4%) and Dicyma olivacea (14.2%). Other species identified were Aspergillus fumigatus and Scedosporium boydii (7.1%). Clinical diagnostic methodologies showed agreement with the molecular identification (data not shown). Cymbopogon citratus EO showed higher antifungal activity than Lavandula pedunculata EO. Highest antifungal activity was observed against Aspergillus fumigatus and Scedosporium boydii (inhibition zone diameter, IZD=90.0mm), up to 7 (Cymbopogon citratus EO) or 3 days of incubation (Lavandula pedunculata EO). While the antifungal activity of Cymbopogon citratus EO was maintained during the study (for Aspergillus fumigatus, Candida albicans and Scedosporium boydii), it decreases with time with Lavandula pedunculata EO. Conclusions: Cymbopogon citratus EO and Lavandula pedunculata EO showed optimal antifungal activity against molds (Aspergillus fumigatus and Scedosporium boydii), up to 3 days of incubation. Against yeasts (Candida albicans and Candida parapsilosis), the EOs showed lower activity. Our study shed light on developing new pharmacological strategies for FK based on EOs extracted from aromatic and medicinal plants.
- Open Access
- 19 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 288, 117368
Municipal secondary-treated effluent data seem to be a suitable source of information for human viral trends
- 19 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 288, 117368
Open AccessMunicipal secondary-treated effluent data seem to be a suitable source of information for human viral trends
- Top Cited PapersOpen Access
- 9 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (5) , 884
Antifungals: From Pharmacokinetics to Clinical Practice
The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins. However, all of these drugs presented one or more limitations associated with adverse reactions, administration route and more recently the development of resistance. To worsen this scenario, there has been an increase in fungal infections, especially in invasive systemic fungal infections that are particularly difficult to diagnose and treat. In 2022, the World Health Organization (WHO) published the first fungal priority pathogens list, alerting people to the increased incidence of invasive systemic fungal infections and to the associated risk of mortality/morbidity. The report also emphasized the need to rationally use existing drugs and develop new drugs. In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics and clinical applications. In parallel, we also addressed the contribution of fungi biology and genetics to the development of resistance to antifungal drugs. Considering that drug effectiveness also depends on the mammalian host, we provide an overview on the roles of therapeutic drug monitoring and pharmacogenomics as means to improve the outcome, prevent/reduce antifungal toxicity and prevent the emergence of antifungal resistance. Finally, we present the new antifungals and their main characteristics.
- 9 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (5) , 884
Top Cited PapersOpen AccessAntifungals: From Pharmacokinetics to Clinical Practice
The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins. However, all of these drugs presented one or more limitations associated with adverse reactions, administration route and more recently the development of resistance. To worsen this scenario, there has been an increase in fungal infections, especially in invasive systemic fungal infections that are particularly difficult to diagnose and treat. In 2022, the World Health Organization (WHO) published the first fungal priority pathogens list, alerting people to the increased incidence of invasive systemic fungal infections and to the associated risk of mortality/morbidity. The report also emphasized the need to rationally use existing drugs and develop new drugs. In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics and clinical applications. In parallel, we also addressed the contribution of fungi biology and genetics to the development of resistance to antifungal drugs. Considering that drug effectiveness also depends on the mammalian host, we provide an overview on the roles of therapeutic drug monitoring and pharmacogenomics as means to improve the outcome, prevent/reduce antifungal toxicity and prevent the emergence of antifungal resistance. Finally, we present the new antifungals and their main characteristics.
- Open Access
- 2 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 825
CuMV VLPs Containing the RBM from SARS-CoV-2 Spike Protein Drive Dendritic Cell Activation and Th1 Polarization
Dendritic cells (DCs) are the most specialized and proficient antigen-presenting cells. They bridge innate and adaptive immunity and display a powerful capacity to prime antigen-specific T cells. The interaction of DCs with the receptor-binding domain of the spike (S) protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pivotal step to induce effective immunity against the S protein-based vaccination protocols, as well as the SARS-CoV-2 virus. Herein, we describe the cellular and molecular events triggered by virus-like particles (VLPs) containing the receptor-binding motif from the SARS-CoV-2 spike protein in human monocyte-derived dendritic cells, or, as controls, in the presence of the Toll-like receptors (TLR)3 and TLR7/8 agonists, comprehending the events of dendritic cell maturation and their crosstalk with T cells. The results demonstrated that VLPs boosted the expression of major histocompatibility complex molecules and co-stimulatory receptors of DCs, indicating their maturation. Furthermore, DCs’ interaction with VLPs promoted the activation of the NF-kB pathway, a very important intracellular signalling pathway responsible for triggering the expression and secretion of proinflammatory cytokines. Additionally, co-culture of DCs with T cells triggered CD4+ (mainly CD4+Tbet+) and CD8+ T cell proliferation. Our results suggested that VLPs increase cellular immunity, involving DC maturation and T cell polarization towards a type 1 T cells profile. By providing deeper insight into the mechanisms of activation and regulation of the immune system by DCs, these findings will enable the design of effective vaccines against SARS-CoV-2.
- 2 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 825
Open AccessCuMV VLPs Containing the RBM from SARS-CoV-2 Spike Protein Drive Dendritic Cell Activation and Th1 Polarization
Dendritic cells (DCs) are the most specialized and proficient antigen-presenting cells. They bridge innate and adaptive immunity and display a powerful capacity to prime antigen-specific T cells. The interaction of DCs with the receptor-binding domain of the spike (S) protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pivotal step to induce effective immunity against the S protein-based vaccination protocols, as well as the SARS-CoV-2 virus. Herein, we describe the cellular and molecular events triggered by virus-like particles (VLPs) containing the receptor-binding motif from the SARS-CoV-2 spike protein in human monocyte-derived dendritic cells, or, as controls, in the presence of the Toll-like receptors (TLR)3 and TLR7/8 agonists, comprehending the events of dendritic cell maturation and their crosstalk with T cells. The results demonstrated that VLPs boosted the expression of major histocompatibility complex molecules and co-stimulatory receptors of DCs, indicating their maturation. Furthermore, DCs’ interaction with VLPs promoted the activation of the NF-kB pathway, a very important intracellular signalling pathway responsible for triggering the expression and secretion of proinflammatory cytokines. Additionally, co-culture of DCs with T cells triggered CD4+ (mainly CD4+Tbet+) and CD8+ T cell proliferation. Our results suggested that VLPs increase cellular immunity, involving DC maturation and T cell polarization towards a type 1 T cells profile. By providing deeper insight into the mechanisms of activation and regulation of the immune system by DCs, these findings will enable the design of effective vaccines against SARS-CoV-2.
- 1 November 2022
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 30 (6)
Test-Based Strategy to Follow up an Immunocompromised Patient Diagnosed With COVID-19
Immunocompromised patients frequently present a prolonged viral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection in respiratory samples and are unrecognized sources of transmission. It is therefore important to determine their infectivity potential to establish the adequate follow-up and quarantine measures. We present a test-based strategy to follow up an immunocompromised patient fully vaccinated for SARS-CoV-2, diagnosed with COVID-19 that 3 months after reaching the clinical criteria of cure presented a reduced cycle threshold value in a real-time polymerase chain reactive SARS-CoV-2 test and a positive antigen SARS-CoV-2 test, while being asymptomatic.
- 1 November 2022
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 30 (6)
Test-Based Strategy to Follow up an Immunocompromised Patient Diagnosed With COVID-19
Immunocompromised patients frequently present a prolonged viral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection in respiratory samples and are unrecognized sources of transmission. It is therefore important to determine their infectivity potential to establish the adequate follow-up and quarantine measures. We present a test-based strategy to follow up an immunocompromised patient fully vaccinated for SARS-CoV-2, diagnosed with COVID-19 that 3 months after reaching the clinical criteria of cure presented a reduced cycle threshold value in a real-time polymerase chain reactive SARS-CoV-2 test and a positive antigen SARS-CoV-2 test, while being asymptomatic.
- 19 June 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 2227-2231
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19
Patients with coronavirus disease‐2019 may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral clearance profile is crucial to establish a re‐testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS‐CoV‐2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative reverse transcription‐polymerase chain reaction (RT‐PCR) tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT‐PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than 2 weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead.
- 19 June 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 2227-2231
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19
Patients with coronavirus disease‐2019 may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral clearance profile is crucial to establish a re‐testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS‐CoV‐2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative reverse transcription‐polymerase chain reaction (RT‐PCR) tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT‐PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than 2 weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead.
- Open Access
- 12 December 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-6
Thrombophilic risk factors for retinal vein occlusion
The aim is to study risk factors for retinal vein occlusion (RVO), such as thrombophilic and cardiovascular risk factors (CRF). A retrospective consecutive case series of 60 patients with RVO was made, tested for CRF, hyperhomocysteinemia, lupic anticoagulant, antiphospholipid antibody and 5 gene variants: factor V (FV) Leiden (G1691A), factor II (PT G20210A), 5,1-methylenetetra-hydrofolate reductase (MTHFR; 677 C > T and 1298 A > C), plasminogen activator inhibitor 1 (PAI-1; 4 G/5 G). More than 1 CRF were present in 36 patients (60%), which had a significantly higher mean age at diagnosis (66.7 ± 12.9 versus 59.5 ± 13.7 with ≤1 CRF, [t(57) = −2.05, p = 0.045, d = 0.54). Patients with thermolabile MTHFR forms with decreased enzyme activity (T677T or C677T/A1298C) had a significant lower mean age [57.6 ± 15.1; t (58) = 3.32; p = 0.002; d = 0.846] than patients with normal MTHFR enzyme activity (68.5 ± 10.2). Regarding CRF and thermolabile forms of MTHFR, the mean age at diagnosis could be significantly predicted [F(2,56) = 7.18; p = 0.002] by the equation: 64.8 − 10.3 × (thermolabile MTHFR) − 5.31 × ( ≤ 1CRF). Screening of MTHFR polymorphisms may be useful in younger RVO patients, particularly when multiple CRF are absent.
- 12 December 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-6
Open AccessThrombophilic risk factors for retinal vein occlusion
The aim is to study risk factors for retinal vein occlusion (RVO), such as thrombophilic and cardiovascular risk factors (CRF). A retrospective consecutive case series of 60 patients with RVO was made, tested for CRF, hyperhomocysteinemia, lupic anticoagulant, antiphospholipid antibody and 5 gene variants: factor V (FV) Leiden (G1691A), factor II (PT G20210A), 5,1-methylenetetra-hydrofolate reductase (MTHFR; 677 C > T and 1298 A > C), plasminogen activator inhibitor 1 (PAI-1; 4 G/5 G). More than 1 CRF were present in 36 patients (60%), which had a significantly higher mean age at diagnosis (66.7 ± 12.9 versus 59.5 ± 13.7 with ≤1 CRF, [t(57) = −2.05, p = 0.045, d = 0.54). Patients with thermolabile MTHFR forms with decreased enzyme activity (T677T or C677T/A1298C) had a significant lower mean age [57.6 ± 15.1; t (58) = 3.32; p = 0.002; d = 0.846] than patients with normal MTHFR enzyme activity (68.5 ± 10.2). Regarding CRF and thermolabile forms of MTHFR, the mean age at diagnosis could be significantly predicted [F(2,56) = 7.18; p = 0.002] by the equation: 64.8 − 10.3 × (thermolabile MTHFR) − 5.31 × ( ≤ 1CRF). Screening of MTHFR polymorphisms may be useful in younger RVO patients, particularly when multiple CRF are absent.
- Open Access
- 1 December 2019
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 12 (8) , 3652-3666
Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves
The hepatocellular carcinoma, a primary malignancy of the liver, has a very poor prognosis and a lower survival rate. Moreover, the inefficacy of conventional therapies emphasizes the importance of discovering new bioactive compounds. Several studies clearly state that plant-derived polyphenols, namely ellagitannins, have several health benefits. Fragaria vesca leaves contain high amounts of polyphenols, being especially rich in ellagitannins. Therefore, this study aimed to characterize an ellagitannin-enriched fraction (EEF) from F. vesca leaves and to unveil the anticancer potential of this fraction on human hepatocellular carcinoma cells.The analysis of EEF by HPLC-PDA-ESI/MSn allowed the detection of 12 ellagitannins. The cell viability of both EEF and crude extract was determined after 24h of cells treatment and the half-maximal inhibitory concentration (IC50) was evaluated. The IC50 of the EEF (113μg/mL) was about 6 times lower than the IC50 of the crude extract (690μg/mL). Furthermore, EEF induced cell cycle arrest at G2/M checkpoint and decreased cell proliferation in a dose-dependent way. This fraction also induced an accumulation of LC3-II protein through blockage of autophagic flux, and inhibited chymotrypsin-like activity of 26S proteasome. These results showed, for the first time, that EEF from F. vesca leaves inhibits both, autophagic and ubiquitin-proteasome system pathways, two main intracellular protein degradation systems that are targets for anticancer therapies. Additionally, a proteomic analysis allowed the identification of 914 proteins, among which 133 were modulated after cells treatment with EEF, most of them related to metabolic pathways. Overall, this study shows that the EEF from F. vesca leaves decreased cell proliferation, inhibited the proteolytic mechanisms and modulated the metabolic pathways of the cell. Additionally this study points out F. vesca as a source of valuable molecules with anticancer potential, suggesting that ellagitannins, the polyphenols identified in this fraction, could be useful in the development of new fine-tuned therapeutic strategies against carcinogenesis
- 1 December 2019
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 12 (8) , 3652-3666
Open AccessChemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves
The hepatocellular carcinoma, a primary malignancy of the liver, has a very poor prognosis and a lower survival rate. Moreover, the inefficacy of conventional therapies emphasizes the importance of discovering new bioactive compounds. Several studies clearly state that plant-derived polyphenols, namely ellagitannins, have several health benefits. Fragaria vesca leaves contain high amounts of polyphenols, being especially rich in ellagitannins. Therefore, this study aimed to characterize an ellagitannin-enriched fraction (EEF) from F. vesca leaves and to unveil the anticancer potential of this fraction on human hepatocellular carcinoma cells.The analysis of EEF by HPLC-PDA-ESI/MSn allowed the detection of 12 ellagitannins. The cell viability of both EEF and crude extract was determined after 24h of cells treatment and the half-maximal inhibitory concentration (IC50) was evaluated. The IC50 of the EEF (113μg/mL) was about 6 times lower than the IC50 of the crude extract (690μg/mL). Furthermore, EEF induced cell cycle arrest at G2/M checkpoint and decreased cell proliferation in a dose-dependent way. This fraction also induced an accumulation of LC3-II protein through blockage of autophagic flux, and inhibited chymotrypsin-like activity of 26S proteasome. These results showed, for the first time, that EEF from F. vesca leaves inhibits both, autophagic and ubiquitin-proteasome system pathways, two main intracellular protein degradation systems that are targets for anticancer therapies. Additionally, a proteomic analysis allowed the identification of 914 proteins, among which 133 were modulated after cells treatment with EEF, most of them related to metabolic pathways. Overall, this study shows that the EEF from F. vesca leaves decreased cell proliferation, inhibited the proteolytic mechanisms and modulated the metabolic pathways of the cell. Additionally this study points out F. vesca as a source of valuable molecules with anticancer potential, suggesting that ellagitannins, the polyphenols identified in this fraction, could be useful in the development of new fine-tuned therapeutic strategies against carcinogenesis